Spots Global Cancer Trial Database for A Phase III Study of Re-Irradiation in Recurrent Glioblastoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase III Study of Re-Irradiation in Recurrent Glioblastoma
Official Title: A Randomized Phase III Study of Re-Irradiation in Recurrent Glioblastoma
Study ID: NCT01830101
Conditions
Study Description
Brief Summary: The investigators hope to improve overall median survival of patients with recurrent Glioblastoma by investigating continuous low-dose daily Temozolomide plus or minus five treatments of re-irradiation.
Detailed Description: This is a stratified study for patients with recurrent intracranial glioblastoma or gliosarcoma previously treated with concurrent chemoradiation presenting radiographic progression or recurrence of tumour. Patients are stratified by extent of resection, time to re-irradiation and re-irradiation volume.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cross Cancer Institute, Edmonton, Alberta, Canada
Contact Details
Name: Samir Patel, MD
Affiliation: Cross Cancer Institute
Role: PRINCIPAL_INVESTIGATOR
Name: Gerald Lim, MD
Affiliation: Tom Baker Cancer Centre
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
